Today’s quick-read news highlights brought to you by Impactiviti:
>> Ovarian cancer drug (Merck/AstraZeneca) gets expanded use approval from FDA.
>> $465M: The price tag misclassifying a EpiPen (Mylan)
>> Pfizer gets FDA approval for drug to treat rare ALL cancer.
Looking to identify the best outsource vendors for your needs? Need on-boarding and developmental training on project/vendor management? AskSteve@Impactiviti.com
PLUS: we share a weekly e-newsletter with helpful recommendations and resources for commercial pharma, biotech, and medical device professionals. Click to join: